Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluciclovine 18F - Emory University/GE Healthcare/Nihon Medi-Physics

Drug Profile

Fluciclovine 18F - Emory University/GE Healthcare/Nihon Medi-Physics

Alternative Names: 18F-Ge-148; 18F fluciclovine; [18F]-FACBC; Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic-acid; Anti-1-amino-3-F-18-fluorocyclobutane-1-carboxylic-acid; Anti-1-amino-3-fluorine-18-fluorocyclobutane-1-carboxylic acid; Anti-18-F-FACBC; Anti-18F-FABC; Anti-3-18F-FACBC; Anti-F-18-fluorocyclobutane-carboxylic-acid; Axumin; Axumin-PET scan; FACBC; fluciclovine(18F); Fluciclovine-F-18; GE-148; Ge-148-18F; Ge-148-F-18; NMK-36; Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid

Latest Information Update: 28 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emory University
  • Developer Blue Earth Diagnostics; Emory University; GE Healthcare; Memorial Sloan-Kettering Cancer Center; Nihon Medi-Physics; University of Arizona; University of Utah
  • Class Amino acids; Carboxylic acids; Cyclobutanes; Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Prostate cancer
  • Preregistration Glioma
  • Phase III Brain metastases
  • Phase II Bone metastases; Brain cancer
  • Phase I Breast cancer
  • No development reported Glioblastoma; Head and neck cancer; Lung cancer; Parathyroid cancer

Most Recent Events

  • 28 Aug 2023 No recent reports of development identified for phase-I development in Glioblastoma(Diagnosis) in USA (IV, Injection)
  • 05 Jun 2023 Blue Earth Diagnostics completes the phase III REVELATE trial for Brain metastases (Diagnosis) in USA (IV) (NCT04410133)
  • 02 Jun 2023 Efficacy data from the phase II PURSUE trial in Brain metastases presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top